Here’s Why Emerging Marijuana Stock Cara Therapeutics Inc. Surged


Pixabay / StockSnap / CC0 Public Domain

Shares of Cara Therapeutics Inc. (NASDAQ: CARA), a clinical-stage biotech company with a focus on treating pain and pruritus, rocketed higher by as much as 11% during Wednesday’s trading session after providing an update to its phase 3 trial involving kappa opioid receptor agonist CR845.

Before you click the “buy” button, keep two things in mind. First, since Cara has no approved therapies on pharmacy shelves, a failure in any one of its phase trials could wind up pummeling its stock.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts